Replies to post #117723 on Biotech Values

[DewDiligence]

I still think that Roche (and NVS for that matter) had an inkling of this outcome when they launched the DME Phase 3 trials.

The NIH CATT study is double-blinded (“double-masked,” as they prefer to say in ophthalmology), and neither Roche nor NVS is a sponsor. So I’m not sure how these companies would get the results before anyone else.